Navigation Links
BioElectronics Corporation Receives Major Orders From Italian Distributor

ActiPatch(TM) Chosen as A Safe and Effective Alternative to NSAIDs, Such As

Vioxx(R) and Celebrex(R)

FREDERICK, Md., May 5 /PRNewswire-FirstCall/ -- BioElectronics Corporation (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch, with an embedded battery operated microchip delivering weeks of continuous pulsed therapy for a nickel an hour, announced today it has received significant new orders from its Italian distributor, TSS Medical, (Tecnica Scientifica Service). TSS Medical has purchased this additional inventory to meet demand in Italy and other European Union counties. BioElectronics is seeing demand for its product increase significantly in Western Europe, which combined with expanding sales in the U.S. and other countries, is likely to drive quarterly revenues to record levels.

Andrew Whelan, President and CEO of BioElectronics Corp. comments, "These are exciting times for all of us at BioElectronics. We expect demand from Italy to increase over the coming months as the product is rolled out to pharmacies across the country. We have also expanded the relationship with our Italian partner to include distribution to additional areas in Europe for which we have now received an initial stocking order. Many Europeans are very interested in the drug-free nature of our products at a time when NSAIDs, such as Vioxx(R) and Celebrex(R), have been determined to have potentially serious cardiovascular side effects. We believe health consumers with pain and soft tissue injuries will continue to view our proven, state-of-the-art ActiPatch therapy as an effective alternative to pharmaceuticals."

About BioElectronics Corporation

Bioelectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is U.S. Government Food and Drug Administration (FDA) cleared for use in reducing edema (swelling) following blepharoplasty and has no known side effects. The product is also approved by Health Canada for the relief of pain in musculoskeletal complaints and is widely available in pharmacies across Canada. The European Union has also approved ActiPatch as a Class II pulsed electromagnetic medical device as have numerous other international regulatory agencies. Information on ActiPatch and BioElectronics Corp. is available at the following websites:

-- U.S. Consumer

-- Podiatry:

-- Plastic Surgery: and

-- German orthopedic foot & ankle:

-- Italy and Switzerland:

-- BioElectronics Corp:

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Vioxx(R) is a registered trademark of Merck & Company

Celebrex(R) is a registered trademark of Pfizer Inc

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email:

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email:

SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
11. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Post Your Comments:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):